GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell an...
Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TMdrug delive...
Cytiva, a global leader in life sciences, introduces the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant pro...
The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...
Novo Nordisk announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg...
The assembly of the chromosomes, and a set of related biological insights, are among the findings published online November 8 in 10 papers in the journals ...
“We’re seeing increased demand for Parse’s Evercode single cell sequencing solutions across Asia, and we believe our products are poised ...
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maxi...
H.E Dr. Jean Kaseya, Director General of the African Centers for Disease Control and Prevention (Africa CDC), visited SK bioscience t...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
© 2023 Biopharma Boardroom. All Rights Reserved.